Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 255-255-2 | CAS number: 41198-08-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: dermal
Administrative data
- Endpoint:
- short-term repeated dose toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 29 December 1997 to 22 January 1998
- Reliability:
- 1 (reliable without restriction)
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 998
- Report date:
- 1998
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.3200 (Repeated Dose Dermal Toxicity -21/28 Days)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- O-(4-bromo-2-chlorophenyl) O-ethyl S-propyl phosphorothioate
- EC Number:
- 255-255-2
- EC Name:
- O-(4-bromo-2-chlorophenyl) O-ethyl S-propyl phosphorothioate
- Cas Number:
- 41198-08-7
- Molecular formula:
- C11H15BrClO3PS
- IUPAC Name:
- 4-bromo-2-chlorophenyl ethyl (propylsulfanyl)phosphonate
- Test material form:
- liquid
Constituent 1
Test animals
- Species:
- rabbit
- Strain:
- New Zealand White
- Sex:
- male/female
Administration / exposure
- Type of coverage:
- semiocclusive
- Vehicle:
- other: 0.5% Tween 80 in distilled water
- Analytical verification of doses or concentrations:
- yes
- Duration of treatment / exposure:
- 6 hrs/day
- Frequency of treatment:
- In total 21 days (5 days/week for the first 14 days and daily thereafter)
Doses / concentrations
- Remarks:
- Doses / Concentrations:0, 2.5, 5, 10 mg/kgBasis:nominal per unit body weight
- No. of animals per sex per dose:
- 10 animals per sex for 0, 2.5 and 5 mg/kg gps11 males and 9 females for 10 mg/kg gp
- Control animals:
- yes, concurrent vehicle
Results and discussion
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 2.5 mg/kg bw/day
- Sex:
- male/female
- Basis for effect level:
- other: Inhibition of brain cholinesterase activity by more than 20% at 5 mg/kg/day and higher
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
No treatment related mortality occurred. No signs of irritation were detected at the skin application site.
Bodyweight and food consumption was unaffected. No ocular changes were seen and no effects were recorded on haematological parameters. The evaluation or organ weights did not reveal any treatment-related changes. Upon microscopic examination, all treated groups were observed to have an increased incidence of acanthosis at the skin application site.
Table 7.5.2 -2: AChE % inhibition
Dose (mg/kg/day) |
Plasma |
RBC |
Brain |
|||||||||
Male |
Sig |
Female |
Sig |
Male |
Sig |
Female |
Sig |
Male |
Sig |
Female |
Sig |
|
2.5 |
86 |
* |
81 |
* |
47 |
* |
58 |
* |
14 |
* |
16 |
NS |
5 |
97 |
* |
95 |
* |
72 |
* |
79 |
* |
33 |
* |
33 |
* |
10 |
97 |
* |
98 |
* |
84 |
* |
90 |
* |
47 |
* |
47 |
* |
* p<0.05; ** P<0.01
The dermal application of CGA 1324 tech, at >2.5 mg/kg resulted in dose related inhibition of the cholinesterase activities in erythrocyte and brain of male and female rabbits. Whilst almost complete inhibition of plasma cholinesterase was observed, erythrocyte and brain cholinesterase activities are considered more relevant markers of activity.The degree of acetyl cholinesterase in erythrocytes and brain was less severe.
Applicant's summary and conclusion
- Conclusions:
- Under the conditions of this test, dermal treatment with CGA 15324 tech. was well tolerated. There was no irritating effect on the skin, but an increased incidence of acanthosis at the application site was observed in all treated groups. However the severity of ancanthosis did not increase in a dose related manner, therefore this was not considered toxicologically relevant. The NOAEL was deemed to be 2.5 mg/kg/day, based on significant inhibition of this enzyme at doses of 5 mg/kg/day and greater.
- Executive summary:
Profenofos was administered via the dermal route tp New Zealand White rabbits subjected to repeated dermal application under sem-occulsive conditions for 22 days on a 5 day/week basis during weeks 1 and 2 and daily from day 15 to 22. The exposure period was 6 hours/day. Test material doses of 0, 2.5, 5 and 10 mg/kg/day were applied to 10 rabbits/sex/group.
The treatment produced no significant clinical signs, no effect on mean body weights or food consumption. No signs of irritation occured at the application site. No ocular changes were seen and no effect on haematological parameters. Organ weights did not reveal any treatment related effects. Macroscopic post mortem examination did not indicate any treatment related changes. Upon microscopic examination all treated groups were observed to have an increased incidence of acanthosis at the skin application site.
A treatment related inhibition of cholinesterase activities in plasma (butyl form), erythrocyte and brain (the acetyl form in both cases) was seen at all doses tested. At the end of the study there was a statisically significant decrease in plasma activity, with almost complete inhibition observed in both genders at all doses tested. Erythrocyte activity ranged from 47 to 90% in male and females, with statistically significant brain cholinesterase inhibition inexcess of 20% observed at doses of 5 mg/kg/day and greater.
The author of the study concluded that no NOAEL could be established, due to acanthosis observed at all doses levels. However, as the severity of ancanthosis was not considered dose related and the severity never increased, this was not considered toxicologically relevant. Whilst statistically significant inhibition of erythrocyte cholinesterase activity was observed at the lowest dose of 2.5 mg/kg/day and greater, guidance set out in the JMPR review (2000) states that ‘inhibition of brain acetylcholinesterase activity and clinical signs to be the primary endpoint of concern in toxicological studies’, whilst ‘inhibition of erythrocyte acetylcholinesterase activity is also considered to be an adverse effect, insofar as it is used as a surrogate for brain and peripheral nerve acetylcholinesterase inhibition, when data on the brain enzyme are not available’. In this study, brain cholinesterase activity was also measured, with significant inhibition in (excess of 20%) was observed at levels of 5 mg/kg/day and greater. Therefore the NOAEL for brain cholinesterase activity was 2.5 mg/kg/day, with no clinical signs of toxicity associated with cholinesterase inhibition.
References:
JMPR (2000). Pesticide residues. Guidelines for the preparation of toxicological working papers for the WHO core assessment group of the Joint Meeting on Pesticide Residues. Geneva, Switzerland, December 2000.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.